🇺🇸 FDA
Pipeline program

methylprednisolone

199/11692

Phase 3 small_molecule completed

Quick answer

methylprednisolone for Spinal Cord Injury is a Phase 3 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Spinal Cord Injury
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials